Bifidobacterium growth promoting composition

Abstract

The present invention belongs to the technical fields of microorganisms and culture media, and specifically relates to a composition for promoting the growth of bifidobacteria, which comprises β-glucan, N-acetylneuraminic acid, and lactoferrin, and has a mass ratio of the β-glucan, N-acetylneuraminic acid, and lactoferrin of (0.10-0.60):(0.08-0.70):(0.018-0.20) in terms of dry weight. This composition may be a culture medium having an excellent effect of promoting the growth of bifidobacteria under anaerobic conditions, or a food composition that can promote the growth of bifidobacteria in the human intestine after ingestion and further improve intestinal health.

Description

[Technical Field]

[0001] This invention belongs to the field of microorganisms and culture media, and more specifically, relates to a composition for promoting the growth of Bifidobacterium. [Background technology]

[0002] Beta-glucans are widely present in the cell walls of microorganisms (e.g., yeast, bacteria, and fungi) and grains (e.g., barley, wheat, and oats), and are the main building blocks of biological cell walls, possessing various structures and functions. Microbial beta-glucans often contain β-1,6-glycosidic bonds in their branched chains, with glucose linked via β-1,3-glycosidic bonds to form the main body. Plant-derived beta-glucans, on the other hand, contain β-1,4-glycosidic bonds in addition to β-1,3-glycosidic and β-1,6-glycosidic bonds. The health-promoting effects of beta-glucans, such as antioxidant, diabetes prevention, anti-inflammatory, and anti-obesity functions, have been widely studied. Beta-glucans cannot be hydrolyzed under the environmental conditions of saliva, stomach, and small intestine, and have been reported to exhibit low bioavailability in the upper digestive tract, similar to other dietary fibers, passing through the digestive system undegraded and safely reaching the intestinal tract. Beta-glucans can regulate the structure and composition of the gut flora by inhibiting the growth of harmful gut bacteria and promoting the growth of beneficial gut bacteria. Reference 1 discloses a complex prebiotic containing inulin, galactooligosaccharides, xylitol, beta-glucans, and manno-oligosaccharides for increasing the numbers of intestinal Lactobacillus and intestinal Bifidobacterium bacteria.

[0003] N-Acetylneuraminic Acid (NANA), commonly known as sialic acid, is an endogenous nutrient monosaccharide. N-Acetylneuraminic Acid plays a central role in brain function development, particularly in the post-translational modification of neural cell adhesion molecules (NCAMs). N-Acetylneuraminic Acid has been suggested to have potential and selective prebiotic activity against Bifidobacteria. Recent studies have shown that Bifidobacterium pseudocatenulatum Bif4, a symbiotic bacterium in the infant gut, contains 41 genes responsible for central carbohydrate metabolism and possesses a gene cluster for the uptake and metabolism of free N-Acetylneuraminic Acid. Through this mechanism, this strain can utilize free N-Acetylneuraminic Acid released from other gut symbionts, positively impacting gut health. Reference 2 discloses that the growth of Bifidobacteria can be regulated using a combination of oligosaccharides found in breast milk (2'-fucosyl lactose, 3'-sialyl lactose, and 6'-sialyl lactose). Reference 3 discloses that a prebiotic composition of sialic acid oligosaccharides and fusion oligosaccharides can increase the relative abundance of beneficial bacteria in the gut, such as Bifidobacteria, Lactobacillus, and Bacteroides flavellis, and decrease the relative abundance of intestinal pathogens.

[0004] Lactoferrin is considered a safe and effective ingredient that can promote iron absorption in humans, regulate cell growth, scavenge free radicals, and suppress the production of several toxic compounds. Furthermore, lactoferrin possesses antibacterial, anti-inflammatory, and anticancer activity, highlighting the therapeutic value of this multifunctional protein. Reference 4 discloses the use of lactoferrin in promoting the growth of Bifidobacterium lactobacillus. Reference 5 discloses that a composition of lactoferrin and / or lactoferrin hydrolysate with human milk oligosaccharides can synergistically promote the growth of Bifidobacterium bacteria.

[0005] Bifidobacterium pseudocatenulatum is a dominant bifidobacterium in the gut of healthy adults, is universally present in people of all age groups, and has a rich variety of strains. Several strains of this species have been shown to have probiotic functions that improve glycolipid metabolism, regulate the immune system, and alleviate anxiety and depression. However, because Bifidobacterium pseudocatenulatum is not included in the list of bacterial species permitted for use in legally approved foods, it is not possible to increase its abundance in the human gut by directly supplementing it exogenously. Only indirect stimulation of Bifidobacterium pseudocatenulatum growth can be achieved by exogenously supplementing specific substances. Reference 6 discloses the assimilation effect of Bifidobacterium on human milk oligosaccharides. Reference 7 discloses that Bifidobacterium pseudocatenulatum can efficiently utilize galactooligosaccharides. Previously, most of the technologies investigating substances that promote the growth of Bifidobacterium pseudocatenulatum have focused on galactooligosaccharides and human milk oligosaccharides. However, no technologies have described the effects of β-glucan, N-acetylneuraminic acid, and lactoferrin compositions on promoting the growth of Bifidobacterium pseudocatenulatum. Furthermore, the effects of dosage on compositions that promote the growth of specific Bifidobacteria have not been reported in previous technologies. [Prior art documents] [Patent Documents]

[0006] Cited document 1: CN108777998B Cited document 2:EP14177597 Cited document 3: EP13775460 Cited document 4: CN112375727B Cited document 5: CN113950247A Cited document 6: CN111935995A Cited document 7: CN113122471B [Overview of the Initiative] [Problems that the invention aims to solve]

[0007] The conventional technologies described above do not adequately address the research on substances that promote the growth of Bifidobacterium pseudocatenulatum. Furthermore, the present invention aims to develop a composition that promotes the growth of Bifidobacterium, particularly Bifidobacterium pseudocatenulatum, in the intestines, by examining the utilization capacity of Bifidobacterium pseudocatenulatum in β-glucan, N-acetylneuraminic acid, lactoferrin, and their compositions, and by examining the dosage effects of the three substances and compositions. [Means for solving the problem]

[0008] To solve the problems of the prior art described above, the present invention provides the following embodiments.

[0009] [1] First, the present invention relates to a culture medium composition comprising basic nutritional components and additive components including β-glucan, N-acetylneuraminic acid, and lactoferrin, The present invention provides a culture medium composition in which the mass ratio of β-glucan, N-acetylneuraminic acid, and lactoferrin is (0.10~0.60):(0.08~0.70):(0.018~0.20) by dry weight. [2] The composition according to [1], wherein the β-glucan is yeast β-glucan, and the N-acetylneuraminic acid is N-acetylneuraminic acid derived from milk, or N-acetylneuraminic acid derived from swiftlet nest, or N-acetylneuraminic acid obtained by biofermentation. [3] The composition according to [1] or [2], wherein the basic nutritional components include one or more of the following: protein components, lipid components, sugar components, vitamin components, mineral components, and pH adjusting components. [4]. Use of the composition according to any one of [1] to [3] in promoting the growth of bifidobacteria, wherein the composition is used to promote the growth of bifidobacteria under anaerobic conditions. [5] The present invention further provides a composition having an effect of promoting the growth of intestinal bifidobacteria, comprising β-glucan, N-acetylneuraminic acid, and lactoferrin, wherein the mass ratio of the β-glucan, N-acetylneuraminic acid, and lactoferrin is (0.10~0.60):(0.08~0.70):(0.018~0.20) by dry weight. [6]. The composition having an effect of promoting the growth of intestinal bifidobacteria as described in [5], wherein the bifidobacteria comprises one or more of the following: Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium longum, and Bifidobacterium breve. [7] A composition having the effect of promoting the growth of intestinal bifidobacteria as described in [5] or [6], optionally containing other nutritional components. [8] A composition having the effect of promoting the growth of intestinal bifidobacteria as described in any one of [5] to [7], which is a liquid, semi-solid, or solid. [9]. Furthermore, the present invention provides a food product comprising a composition having the effect of promoting the growth of intestinal bifidobacteria as described in any one of [5] to [8], or a food product prepared from such composition.

[10] Foods which are powdered drinks, bakery foods, beverages, candies, milk and dairy products, fermented products, wheat flour products or oral preparations, preferably the oral preparation comprising tablets, pills, granules, powders, teas, capsules and oral liquid preparations, as described in [9]. [Effects of the Invention]

[0010] By implementing the above embodiments, the present invention can achieve the following effects. First, different from the prior art that only examined the growth effect of some substances alone (such as human milk oligosaccharides, galactooligosaccharides) on Bifidobacterium pseudocatenulatum, when examining the growth effect of a composition of β-glucan, N-acetylneuraminic acid and lactoferrin on Bifidobacteria, especially Bifidobacterium pseudocatenulatum, it was surprisingly found that the growth promoting effect of the composition on Bifidobacteria was more remarkable compared to β-glucan, N-acetylneuraminic acid or lactoferrin alone, and there was a synergistic effect among β-glucan, N-acetylneuraminic acid and lactoferrin.

[0011] In addition, in the present invention, the necessary contents of each component in the composition were comprehensively examined. When the growth of Bifidobacteria, especially Bifidobacterium pseudocatenulatum, was relatively good under the condition of a single substance, the dosage of each component in the composition was designed, and then increased and decreased respectively, and finally an appropriate dosage range was determined. The composition according to the present invention can supply a lot of nutrients to Bifidobacteria under the appropriate dosage conditions of each component, extend the stationary phase of Bifidobacteria, delay the decline phase, and effectively promote the growth of Bifidobacteria.

[0012] Furthermore, the above composition can also promote the increase of Bifidobacterium pseudocatenulatum, a potential probiotic in the intestinal tract, and has the effect of improving intestinal health.

Brief Description of the Drawings

[0013] [Figure 1] It is a figure showing the observation results of the growth of Bifidobacterium pseudocatenulatum cultured for 36 hours in MRS medium with different glucose addition amounts. Here, the glucose concentration of the medium in the test tube is 2 g / 100 mL, 1 g / 100 mL, 0.5 g / 100 mL, 0.25 g / 100 mL, 0.15 g / 100 mL in order from the left. [Figure 2]These are growth curves of Bifidobacterium pseudocatenulatum in MRS medium supplemented with different doses of β-glucan. [Figure 3] These are growth curves of Bifidobacterium pseudocatenulatum in MRS medium supplemented with different doses of N-acetylneuraminic acid. [Figure 4] These are growth curves of Bifidobacterium pseudocatenulatum in MRS medium supplemented with different doses of lactoferrin. [Figure 5] These are growth curves of Bifidobacterium pseudocatenulatum in MRS medium supplemented with different doses of β-glucan, N-acetylneuraminic acid, and lactoferrin compositions. [Figure 6] The OD values ​​of stationary-stage Bifidobacterium pseudocatenulatum in MRS medium supplemented with different doses of β-glucan, N-acetylneuraminic acid, and lactoferrin compositions are shown. Here, lowercase letters indicate the significance of the difference in OD values ​​between groups (p<0.05). If the OD values ​​of both groups do not contain the same letter, it indicates a significant difference between them; otherwise, it indicates no significant difference. [Figure 7] This is a statistical result of the time course of ΔOD600nm of Bifidobacterium pseudocatenulatum bacterial suspension in MRS medium supplemented with different doses of β-glucan, N-acetylneuraminic acid, and lactoferrin compositions. [Modes for carrying out the invention]

[0014] Embodiments of the present invention will be described below, but the present invention is not limited thereto. The present invention is not limited to the configurations described below, and various modifications are possible within the scope of the claims. Embodiments and examples obtained by appropriately combining the technical means disclosed in different embodiments and examples are also included in the technical scope of the present invention.

[0015] definition In this specification, a numerical range expressed as "Numerical A to Numerical B" means a range that includes the limit values ​​A and B. In this specification, numerical ranges expressed as "greater than or equal to" or "less than or equal to" mean the numerical range that includes those numbers. In this specification, "may" means that the process may be performed and may not be performed. In this specification, “optional” means the use or non-use of the substance, component, process, application conditions, or other elements. Unless otherwise specified in this specification, "room temperature" as used generally refers to a temperature of 23±2℃. In this specification, all unit names used are International Standard Units, and unless otherwise specified, "%" refers to weight or mass percentage. In this specification, the terms “approximately,” “basic,” or “substantial” are used to indicate that a value includes the standard deviation of the error of the apparatus or method used to determine the value. All numerical ranges and parameters used to define the present invention are approximations, but they reproduce the numerical values ​​relating to specific examples as accurately as possible. However, any numerical value inherently includes the standard deviation due to the measuring apparatus or method described above. Therefore, unless otherwise specified, all ranges, numbers, numerical values, and percentages used in the present invention should be understood to be modified by “approximately.” Here, “approximately” usually means that the standard deviation between the actual numerical value and the theoretical model or theoretical data is within 3%, preferably 2%, and more preferably 1%. In this specification, references to “several / preferred embodiments,” “another / preferred embodiment,” “embodiment,” etc., mean that certain elements (e.g., features, structure, properties, and / or characteristics) described in relation to an embodiment are included in at least one embodiment and may or may not be present in other embodiments. Furthermore, these elements can be combined in any suitable manner in various embodiments. Furthermore, unless otherwise defined, other technical and scientific terms used in this invention have the same meanings as those commonly understood by those skilled in the art to which this invention pertains.

[0016] This invention is primarily based on the following findings. First, in some typical embodiments of the present invention, when Bifidobacterium was cultured in MRS medium with glucose addition amounts of 2 g / 100 mL, 1 g / 100 mL, 0.5 g / 100 mL, 0.25 g / 100 mL, and 0.15 g / 100 mL, it was found that the growth rate of Bifidobacterium was appropriate in MRS medium with a glucose addition amount of 0.15 g / 100 mL, making it suitable for subsequent experiments.

[0017] Furthermore, in this invention, we have found that β-glucan alone can promote the growth of Bifidobacterium, and the amount of β-glucan added to the culture medium should be 0.2550 to 0.5738 mg / mL; N-acetylneuraminic acid alone can promote the growth of Bifidobacterium, and the amount of N-acetylneuraminic acid added to the culture medium should be 0.2058 to 0.5145 mg / mL; and lactoferrin alone can promote the growth of Bifidobacterium, and the amount of lactoferrin added to the culture medium should be, for example, 0.0459 mg / mL.

[0018] Furthermore, the present invention employs a method of combining multiple substances, and because different substances have different properties and different probiotic degradation mechanisms, a combination of multiple substances can more effectively promote the growth of beneficial bacteria than a single substance. Through extensive experiments, the present invention has found that adding β-glucan, N-acetylneuraminic acid, and lactoferrin to a culture medium in specific proportions (e.g., concentrations) can more effectively promote the growth of bifidobacteria, particularly Bifidobacterium pseudocatenulatum. Against this backdrop, the present invention provides a composition that can effectively promote the growth of bifidobacteria, exhibiting superior effects compared to the addition of each of the three substances individually, and demonstrating the best effect with a stationary growth rate 1.8 times that of the blank control group.

[0019] Embodiments of the present invention will be described further below.

[0020] Culture medium composition First, the present invention provides a culture medium composition comprising basic nutritional components and additive components including β-glucan, N-acetylneuraminic acid, and lactoferrin. This composition demonstrates a significant synergistic effect and can effectively promote the growth of bifidobacteria, particularly Bifidobacterium pseudocatenulatum, under anaerobic conditions.

[0021] (Basic nutritional components) The basic nutritional components that can be used in the culture medium composition of the present invention are not particularly limited and may be those commonly used in conventional MRS culture media. In some embodiments, such basic nutritional components include one or more of the following: protein components, lipid components, sugar components, vitamin components, mineral components, and pH adjusting components.

[0022] In this invention, there are no particular requirements regarding the proportions of these components used; they can be set according to the usual technical guidelines in the prior art. In some preferred embodiments of the present invention, the culture medium may contain components such as tryptone, yeast powder, beef extract, glucose, magnesium sulfate heptahydrate, manganese sulfate monohydrate, sodium acetate, diammonium hydrogen citrate, dipotassium hydrogen phosphate trihydrate, and polysorbate 80.

[0023] (β-glucan) Beta-glucan is a type of polysaccharide derived from cell walls. Current research indicates that beta-glucan has health-promoting effects such as immunomodulatory, antitumor, and blood lipid-lowering effects, and can effectively promote the establishment of probiotics such as Bifidobacterium in the gut, thereby effectively alleviating various gastrointestinal digestive system problems. Currently, the extraction process for β-glucan is relatively mature, therefore, in this invention, the extraction process for β-glucan is not particularly limited. For example, it can be extracted by acid hydrolysis using acetic acid, alkaline extraction using sodium hydroxide, or a combination of acid and alkali. Furthermore, finished β-glucan products can also be obtained commercially.

[0024] Furthermore, the present invention does not particularly limit the origin of the β-glucan, but it may be derived from various plants, fungi, or algae, for example, oats, barley, yeast, mushrooms, or seaweed. In addition, in some preferred embodiments of the present invention, from the viewpoint of better promoting the growth of Bifidobacteria, the above β-glucan may be yeast-derived β-glucan, which is a high molecular weight polysaccharide having β-1,3-D-glucan as the main chain and β-1,6-D-glucan as the branched chain.

[0025] (N-acetylneuraminic acid) N-acetylneuraminic acid (NANA), also known as sialic acid, is an important component of brain gangliosides. Studies have shown that N-acetylneuraminic acid is widely present in various biological tissues and is an important component of glycoproteins, oligosaccharides, and glycolipids. It usually exists as a glycoside at the terminals of glycoproteins and glycolipids, and has been found to be particularly abundant in the mammalian brain, nerve tissue, blood, submandibular gland, mucin, and colostrum. N-acetylneuraminic acid has beneficial effects in various aspects, including promoting intellectual development, improving intestinal absorption capacity, and enhancing immunity. Furthermore, studies have shown that N-acetylneuraminic acid may have potential and selective prebiotic activity against Bifidobacterium. Currently, methods for producing N-acetylneuraminic acid mainly include extraction from natural raw materials, chemical synthesis, polymer decomposition, enzyme / immobilized enzyme methods, and microbial fermentation. In the present invention, the origin and extraction process of N-acetylneuraminic acid are not particularly limited. For example, it may be N-acetylneuraminic acid derived from milk, N-acetylneuraminic acid derived from swiftlet nests, or N-acetylneuraminic acid obtained by biofermentation, or it may be commercially available finished N-acetylneuraminic acid.

[0026] (Lactoferrin) Lactoferrin (LF) is an iron-binding glycoprotein with a molecular weight of 80 kDa and belongs to the transferrin family. Lactoferrin is widely distributed in human and mammalian milk, as well as in various tissues and their secretions, with high levels in milk, and especially in bovine colostrum. Studies have shown that lactoferrin has a broad antibacterial spectrum, antiviral effects, regulates the balance of iron in the body, regulates bone marrow cell production, promotes cell proliferation, regulates the body's immune function, enhances the body's immunity, and suppresses human tumor cells. Furthermore, studies have shown that lactoferrin can promote the growth of Bifidobacteria and Lactobacillus, thus maintaining a healthy intestinal microbial environment. The present invention is not particularly limited in terms of the origin and production method of lactoferrin. For example, lactoferrin can be isolated from milk using separation and purification methods such as chromatography or ultrafiltration, or lactoferrin can be obtained by exogenously expressing it using recombinant protein expression technology. Finished lactoferrin can also be obtained commercially.

[0027] (Synergistic effect) Previous studies on β-glucan, N-acetylneuraminic acid, and lactoferrin have shown that all three may have growth-promoting effects on Bifidobacterium bacteria. However, conventional techniques have only studied each of these substances individually, and there have been no studies or reports on whether they have the ability to promote Bifidobacterium growth through a synergistic effect among the three.

[0028] In this invention, we unexpectedly discovered that the combined use of β-glucan, N-acetylneuraminic acid, and lactoferrin exhibits a synergistic effect in promoting the growth of Bifidobacterium, particularly Bifidobacterium pseudocatenulatum, under anaerobic conditions. The dosage required when using these three substances in combination differs from the dosage required when using each of the three substances individually to promote the growth of Bifidobacterium pseudocatenulatum.

[0029] This invention first designed and investigated the proliferation of Bifidobacterium pseudocatenulatum using a single substance, and found that different doses of the single substance had a proliferative effect on Bifidobacterium pseudocatenulatum.

[0030] In some embodiments, β-glucan alone, when at a concentration of 0.2550 to 0.5738 mg / mL, has the effect of promoting the growth of Bifidobacterium pseudocatenulatum.

[0031] In some embodiments, N-acetylneuraminic acid alone, at a concentration of 0.2058 to 0.5145 mg / mL, has the effect of promoting the growth of Bifidobacterium pseudocatenulatum.

[0032] In some embodiments, lactoferrin alone, at a concentration of 0.0459 mg / mL, has the effect of promoting the growth of Bifidobacterium pseudocatenulatum.

[0033] Further investigation of the present invention revealed that the dosage required when β-glucan, N-acetylneuraminic acid, and lactoferrin are used in combination differs from the dosage required when each of these substances is used individually to promote the growth of Bifidobacterium pseudocatenulatum.

[0034] Specifically, it is as follows:

[0035] In the above culture medium composition, the mass ratio of β-glucan, N-acetylneuraminic acid, and lactoferrin according to the present invention is (0.10~0.60):(0.08~0.70):(0.018~0.20) by dry weight.

[0036] In some preferred embodiments, the mass ratio of β-glucan, N-acetylneuraminic acid, and lactoferrin may be (0.11~0.59):(0.09~0.68):(0.020~0.15), more preferably (0.12~0.55):(0.10~0.60):(0.021~0.11), and exemplary the mass ratio of β-glucan, N-acetylneuraminic acid, and lactoferrin may be 0.255:0.50:0.05, or 0.255:0.21:0.05, or 0.51:0.40:0.09, or 0.51:0.10:0.05, or 0.13:0.57:0.023, etc.

[0037] Furthermore, in the present invention, the amounts used of β-glucan, N-acetylneuraminic acid, and lactoferrin are not limited in principle, as long as they satisfy the above mass ratio and ensure synergistic effects and safety of the amounts used.

[0038] In the present invention, there are no particular limitations on the form of the culture medium composition, but in some embodiments, the culture medium composition according to the present invention may contain a solvent, such as water. Therefore, it may take the form of a liquid (such as an aqueous solution) or a semi-solid (slurry).

[0039] Using a culture medium with the above composition provides excellent growth-promoting effects for Bifidobacteria, particularly Bifidobacterium pseudocatenulatum, under anaerobic conditions.

[0040] A composition having the effect of promoting the growth of intestinal bifidobacteria. Furthermore, the present invention provides a composition having the effect of promoting the growth of intestinal bifidobacteria, comprising the above-mentioned β-glucan, N-acetylneuraminic acid, and lactoferrin, and optionally other nutritional components.

[0041] The relationship between the amounts used of β-glucan, N-acetylneuraminic acid, and lactoferrin can be expressed in the mass ratio relationship of (0.10~0.60):(0.08~0.70):(0.018~0.20). In some preferred embodiments, the mass ratio of β-glucan, N-acetylneuraminic acid, and lactoferrin may be (0.11~0.59):(0.09~0.68):(0.020~0.15), and more preferably (0.12~0.55):(0.10~0.60):(0.021~0.11). Similarly, as long as the above ratios are satisfied, there are no particular restrictions on the respective mass contents of β-glucan, N-acetylneuraminic acid, and lactoferrin in the composition; however, they should be added in accordance with normal usage amounts and the requirements of relevant laws and regulations.

[0042] Furthermore, in some embodiments, the Bifidobacterium according to the present invention includes one or more species from among Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium longum, and Bifidobacterium breve. The above Bifidobacterium species can colonize the human intestine.

[0043] In particular, the composition according to the present invention can promote the growth of Bifidobacterium pseudocatenulatum in the intestines. Bifidobacterium pseudocatenulatum is a beneficial bacterium in the intestines, but it does not belong to the bacterial species permitted for use in food under the law. Therefore, the composition according to the present invention, which has the effect of promoting the growth of intestinal bifidobacteria, is of special significance in that it can promote human health by utilizing the beneficial effects of Bifidobacterium pseudocatenulatum by exerting its growth-promoting effect on Bifidobacterium pseudocatenulatum in the intestines.

[0044] In addition to β-glucan, N-acetylneuraminic acid, and lactoferrin, which are necessary for the composition, the composition having the effect of promoting the growth of intestinal bifidobacteria according to the present invention may optionally contain other nutritional components, such as plants or their extracts, milk-containing components, animal components, functional additives, trace element supplements, and / or any additives that are acceptable as food.

[0045] Plants or plant extracts include fruits such as figs, pomegranates, kiwifruit, mandarins, bitter oranges, pineapples, strawberries, apples, rubber, grapes, pears, cherries, blueberries, blackberries, raspberries, and bilberries, or their extracts; vegetable substances such as onions, cucumbers, tomatoes, cauliflower, carrots, spinach, Chinese broccoli, Brussels sprouts, garlic, basil, and oregano, or their extracts; and rice (Indica rice, etc.). Contains grains or extracts thereof, such as Japonica rice (glutinous rice), grains (wheat, barley, oats, rye), corn, sorghum, millet, foxtail millet, corn kernels, buckwheat, soybeans, broad beans, peas, mung beans, adzuki beans, and kidney beans; substances from nuts or extracts thereof, such as walnuts, pistachios, cashews, hazelnuts, almonds, apricot kernels, pine nuts, peanuts, guazu, chestnuts, macadamia nuts, and ginkgo nuts; and coffee or its extracts.

[0046] Regarding milk-containing components or protein components, the milk-containing components include raw milk, milk powder, whey protein, or dairy products such as cheese derived from cow's (goat's) raw milk. Regarding protein components, they may be derived from plant proteins such as soy protein or peanut protein.

[0047] Animal-derived ingredients include meat product components derived from cattle, goats, fish, or poultry.

[0048] Regarding the fatty components, the fat includes at least one of saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, 1,3-dioleoyl-2-palmitoylglycerol (OPO), DHA, EPA, ARA, and phospholipids. Specifically, the fat includes safflower oil, walnut oil, peanut oil, soybean oil, argan oil, olive oil, tea oil, sasha inchi oil, olive oil, coconut oil, perilla oil, deep-sea fish oil, cocoa cream, palm oil, beef tallow, cream, lard, medium-chain triglyceride, or lecithin.

[0049] Functional additives include vitamins (including one or more of vitamin A, β-carotene, vitamin D3, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, pantothenic acid, folic acid, nicotinic acid, choline, inositol, and biotin), starch, modified starch, amino acids (L-lysine, L-glutamic acid, L-glutamic acid, L-arginine, L-tryptophan, L-glutamine, taurine, L-valine, L-isoleucine, or L-leucine, etc.), herbal medicines or herbal medicine extracts, and dietary fiber (inulin, konjac powder, galactooligosaccharides, fructooligosaccharides, isomaltoligosaccharides, soybean polysaccharides, cyclodextrin, indigestible dextrin, or soybean fiber, etc.).

[0050] Trace element supplements contain one or more metal ion salts of organic acids, such as calcium citrate, L-calcium lactate, calcium hydrogen phosphate, potassium gluconate, sodium citrate, ferrous gluconate, potassium iodide, zinc gluconate, sodium selenite, copper gluconate, chromium sulfate, manganese gluconate, and magnesium gluconate.

[0051] Additives that are permitted as any food include, but are not limited to, solvents, antioxidants, antimicrobial agents, thickeners, diluents, cosolvents, stabilizers, emulsifiers, fillers, disintegrants, lubricants, coatings, anti-caking agents, flavorings, sweeteners, food flavors, and food colorings.

[0052] Furthermore, the present invention is not particularly limited in form to the composition having the above-mentioned effect of promoting the growth of intestinal bifidobacteria, and may be, for example, a liquid, semi-solid, or solid.

[0053] food The present invention provides a food product containing the aforementioned composition or a composition having the effect of promoting the growth of intestinal bifidobacteria. The food of the present invention is not particularly limited, but may typically be a powdered drink, bakery food, beverage, candy, milk and dairy products, fermented products, wheat flour products, or oral preparation.

[0054] The powdered drink may typically be a powdered milk product such as infant formula or adult formula, or it may be instant coffee, grain flour, nut flour, or lotus root powder.

[0055] As for bakery products, they may be bakery cakes or biscuits, etc., with cream, eggs, and baking powder as the main ingredients.

[0056] The beverages may include carbonated drinks, fruit and vegetable juices, functional beverages, tea beverages, dairy beverages, or alcoholic beverages.

[0057] The candy may include hard candies, hard candies with a center filling, fudge, gummy candies, polishing candies, gum-based candies, aerated candies, and tablet candies, etc.

[0058] Milk and dairy products may include raw milk derived from cow's (or goat's) raw milk, powdered milk, whey powder, fermented milk, cheese, or condensed milk.

[0059] Fermented products may typically include fermented milk, fermented soy milk, etc., and may also contain fermented sauces.

[0060] Wheat flour products may include staple foods processed or manufactured using wheat flour as a raw material, as well as grain-based staple foods. Specifically, examples include steamed buns, mochi (rice cakes), noodles, and sweet bean paste staple foods.

[0061] Oral formulations may include tablets, pills, granules, powders, teas, capsules, and oral liquids.

[0062] The food products provided by this invention are, in principle, suitable for all people, especially those with a need to improve their gut health, and it is also possible to adjust the ingredients in the food products to suit the different characteristics of individuals.

[0063] In some embodiments, the β-glucan content is 0.05-0.5%, preferably 0.06-0.4%, more preferably 0.06-0.35%, and even more preferably 0.1-0.25%, relative to the total mass of the food; the N-acetylneuraminic acid content is 0.01-0.3%, preferably 0.015-0.2%, more preferably 0.02-0.15%, and even more preferably 0.025-0.1%; and the lactoferrin content is 0.01-0.1%, preferably 0.01-0.07%, more preferably 0.01-0.05%, and even more preferably 0.01-0.03%. Typically, the food may be powdered milk, particularly infant formula, child formula, or powdered milk for middle-aged and elderly people. [Examples]

[0064] To further clarify the object, technical solutions, and advantages of the present invention, the invention will be described in more detail below with reference to examples. It should be understood that the specific examples described herein are for illustrative purposes only and do not limit the invention. Unless otherwise specified, the reagents, methods, and apparatus used in the present invention are common in the industry.

[0065] The method for producing Bifidobacterium pseudocatenulatum cells according to the following example is as follows: The Bifidobacterium pseudocatenulatum strain (original number: 8-7, hereinafter referred to as "Bifidobacterium pseudocatenulatum") originated from a fecal sample of a healthy infant in Wuxi City, Jiangsu Province, and was preserved at the Biotechnology Center of the School of Food Science, Jiangnan University. The Bifidobacterium pseudocatenulatum was activated through an activation process. First, Bifidobacterium pseudocatenulatum glycerol tubes were cultured in liquid MRS medium at a bacterial load of 2% (V / V) and incubated at 37°C under anaerobic conditions for 36 hours. Subsequently, Bifidobacterium pseudocatenulatum was streaked onto mMRS (mMRS is MRS supplemented with 0.05% cysteine) solid medium and incubated at 37°C under anaerobic conditions for 36 hours to obtain single colonies. Single colonies were collected, inoculated into 5 mL mM RS liquid medium, and activated by culturing at 37°C under anaerobic conditions for 36 hours. Two generations were activated consecutively to obtain an activated solution. The above bacteria can be thawed and activated before being used in subsequent tests.

[0066] Furthermore, the glucans used in the following examples are all commercially available yeast β-glucans.

[0067] Example 1: Growth of Bifidobacterium pseudocatenulatum in MRS medium with different glucose content The above-mentioned Bifidobacterium pseudocatenulatum was inoculated into mMRS liquid medium with different glucose concentrations (2g / 100mL, 1g / 100mL, 0.5g / 100mL, 0.25g / 100mL, and 0.15g / 100mL, respectively), and after anaerobic incubation at 37°C for 48 hours, the growth of Bifidobacterium pseudocatenulatum was observed. As shown in Figure 1 (the glucose concentration in the medium in the test tube decreases from left to right), after 36 hours, Bifidobacterium pseudocatenulatum grew slowly in the mMRS medium containing 0.15g / 100mL of glucose and was hardly able to maintain growth. Therefore, in order to prepare for subsequent experiments to promote the growth of Bifidobacterium pseudocatenulatum using β-glucan, N-acetylneuraminic acid, and lactoferrin, the glucose concentration in the reduced-sugar MRS medium was set to 0.15 g / 100 mL.

[0068] Example 2: Growth of Bifidobacterium pseudocatenulatum in MRS medium with different doses of β-glucan. Based on the standard concentration of commercially available powdered milk, the liquid concentration of β-glucan in that product (0.06375 mg / mL) was used as the standard dose. Based on this standard dose, doses of 1 / 4, 1 / 2, 1, 2, 4, and 9 times (however, 9 times is the maximum amount added according to regulations) were set, resulting in β-glucan concentrations of 0.01594 mg / mL, 0.03188 mg / mL, 0.06375 mg / mL, 0.1275 mg / mL, 0.2550 mg / mL, and 0.5738 mg / mL, respectively. Two generations of continuously activated Bifidobacterium pseudocatenulatum were placed in a sterile centrifuge tube (1 mL), centrifuged at 5000 r / min for 15 minutes, discarded the upper layer to obtain the bacterial sludge, resuspended in 1 mL of sterile saline, and inoculated into reduced-sugar MRS medium with 2% (V / V) inoculum of the six different doses of β-glucan. A blank control was also inoculated into reduced-sugar MRS medium without β-glucan. The plates were placed in a microplate reader and incubated anaerobically at 37°C for 36 hours, during which the OD of the culture medium was observed. 600 The levels were measured at 4-hour intervals. Figure 2 shows the growth curves of Bifidobacterium pseudocatenulatum at different doses of β-glucan.

[0069] As is clear from Figure 2, Bifidobacterium pseudocatenulatum entered the logarithmic growth phase at approximately the same time in media containing six different doses of β-glucan and the control group media. However, compared to the control group, Bifidobacterium pseudocatenulatum showed higher station-phase absorbance values ​​and the highest total bacterial count in media containing 4 times and 9 times the standard dose of β-glucan, particularly when the β-glucan content was 4 times the standard dose. 600 The value was the largest. According to these results, the utilization of β-glucan by Bifidobacterium pseudocatenulatum has a dose-dependent effect, and β-glucan at concentrations 4 to 9 times the standard dose (0.2550 to 0.5738 mg / mL) has the effect of promoting the proliferation of Bifidobacterium pseudocatenulatum.

[0070] Example 3: Growth of Bifidobacterium pseudocatenulatum in MRS medium with different doses of N-acetylneuraminic acid Based on the standard concentration of commercially available infant formula, the liquid concentration of N-acetylneuraminic acid (0.05145 mg / mL) was used as the standard dose. Based on this standard dose, doses were set at 1 / 4, 1 / 2, 1, 2, 4, 10, and 22 times (however, 22 times is the maximum amount added according to regulations), resulting in N-acetylneuraminic acid concentrations of 0.01286 mg / mL, 0.02573 mg / mL, 0.05145 mg / mL, 0.1029 mg / mL, 0.2058 mg / mL, 0.5145 mg / mL, and 1.1319 mg / mL, respectively. Two generations of continuously activated Bifidobacterium pseudocatenulatum were placed in a sterile centrifuge tube (1 mL), centrifuged at 5000 r / min for 15 minutes, discarded the upper layer to obtain the bacterial sludge, resuspended in 1 mL of sterile saline, and inoculated into reduced-sugar MRS medium with 2% (V / V) inoculation of the seven different doses of N-acetylneuraminic acid. As a blank control, the cells were inoculated into reduced-sugar MRS medium without N-acetylneuraminic acid. The plates were placed in a microplate reader and incubated anaerobically at 37°C for 36 hours, during which the OD of the culture medium was observed. 600The levels were measured at 4-hour intervals. Figure 3 shows the growth curves of Bifidobacterium pseudocatenulatum at different doses of N-acetylneuraminate.

[0071] As is clear from Figure 3, in media containing seven different doses of N-acetylneuraminic acid and the control group media, Bifidobacterium pseudocatenulatum entered the logarithmic growth phase at almost the same time. However, compared to the control group, Bifidobacterium pseudocatenulatum showed higher stationary phase absorbance values ​​and the highest total bacterial count in media containing 4 to 10 times the standard dose of N-acetylneuraminic acid. 600 The value was the largest. According to these results, the utilization of N-acetylneuraminic acid by Bifidobacterium pseudocatenulatum has a dose-dependent effect, and it was found that N-acetylneuraminic acid at concentrations 4 to 10 times the standard dose (0.2058 to 0.5145 mg / mL) has the effect of promoting the proliferation of Bifidobacterium pseudocatenulatum.

[0072] Example 4: Growth of Bifidobacterium pseudocatenulatum in MRS medium with different doses of lactoferrin Using the concentration of commercially available powdered milk as a baseline, the liquid lactoferrin concentration of 0.0459 mg / mL was set as the standard dose. Based on this standard dose, two gradients were set upwards (2x and 4x) and two gradients downwards (1 / 2 and 1 / 4) to obtain a total of five different concentrations of lactoferrin cultures. However, the 4x standard dose exceeds the upper limit of the amount permitted by law. Therefore, the lactoferrin concentrations were set to 0.01148 mg / mL, 0.02295 mg / mL, 0.0459 mg / mL, 0.0918 mg / mL, and 0.1500 mg / mL, respectively. Two generations of continuously activated Bifidobacterium pseudocatenulatum were placed in a sterile centrifuge tube (1 mL), centrifuged at 5000 r / min for 15 minutes, discarded the upper layer to obtain the bacterial sludge, resuspended in 1 mL of sterile saline, and inoculated into reduced-sugar MRS medium with 2% (V / V) inoculum of the five different doses of lactoferrin. As a blank control, reduced-sugar MRS medium without lactoferrin was also inoculated. The plates were placed in a microplate reader and incubated anaerobically at 37°C for 36 hours, during which the OD of the culture medium was observed. 600 The levels were measured at 4-hour intervals. The growth curves of Bifidobacterium pseudocatenulatum at different doses of lactoferrin are shown in Figure 4.

[0073] As is clear from Figure 4, in media containing five different doses of lactoferrin and the control group media, Bifidobacterium pseudocatenulatum entered the logarithmic growth phase at approximately the same time. However, compared to the control group, Bifidobacterium pseudocatenulatum showed higher absorbance values ​​and the highest total bacterial count in both the logarithmic growth phase and the stationary phase with the standard dose (1x) of lactoferrin. In the logarithmic growth phase, Bifidobacterium pseudocatenulatum showed the highest OD (Opposition Dioxide Output) in lactoferrin at 1 / 4 and 2x the standard dose. 600 The OD was lower than in the control group, and at the stationary phase, Bifidobacterium pseudocatenulatum was effective at 1 / 2 and 4 times the standard dose of lactoferrin. 600The levels were also lower than in the control group. These results indicate that an appropriate dose of lactoferrin is necessary to promote the proliferation of Bifidobacterium pseudocatenulatum, and that too much or too little does not significantly promote the proliferation of Bifidobacterium pseudocatenulatum. For example, it was found that the standard dose (1x dose) (0.0459 mg / mL) of lactoferrin is suitable for the proliferation of Bifidobacterium pseudocatenulatum.

[0074] Example 5: Growth of Bifidobacterium pseudocatenulatum in MRS medium with different dosage compositions According to Example 2, the appropriate doses of β-glucan to promote the growth of Bifidobacterium pseudocatenulatum were 4 times, then 9 times, and 1 time the standard dose. According to Example 3, the optimal doses of N-acetylneuraminic acid were 4 times, then 10 times, 1 time, and 22 times the standard dose. According to Example 4, the optimal dose of lactoferrin was the standard dose (1 time). β-glucan, N-acetylneuraminic acid, and lactoferrin were combined with the standard dose ratios obtained above that promote the growth of Bifidobacterium pseudocatenulatum (1:4:1, 9:4:1, 4:1:1, 4:10:1, 4:22:1, 4:4:1), and these combined doses were each increased by 2 times (except when exceeding the maximum permitted dose), and then decreased by 2 times. The compositions of β-glucan, N-acetylneuraminic acid, and lactoferrin were obtained using standard dose ratios of 1:4:1, 1 / 2:2:1 / 2, 2:8:2, 9:4:1, 9 / 2:2:1 / 2, 4:1:1, 2:1 / 2:1 / 2, 8:2:2, 4:10:1, 8:20:2, 2:5:1 / 2, 4:22:1, 2:11:1 / 2, 4:4:1, 2:2:1 / 2, and 8:8:2, resulting in a total of 16 different ratios. Two generations of continuously activated Bifidobacterium pseudocatenulatum were placed in a sterile centrifuge tube (1 mL), centrifuged at 5000 r / min for 15 minutes, discarded the upper layer to obtain the bacterial sludge, which was then resuspended in 1 mL of sterile saline. This sludge was then inoculated into reduced-sugar MRS medium containing 16 different doses of β-glucan, N-acetylneuraminic acid, and lactoferrin at a 2% (V / V) inoculation level. As a blank control, the sludge was inoculated into reduced-sugar MRS medium without any added compositions. The plates were placed on a microplate reader and incubated anaerobically at 37°C for 36 hours. During incubation, the OD of the culture medium was observed. 600 The levels were measured at 4-hour intervals. The growth curves of Bifidobacterium pseudocatenulatum in compositions with different dosages are shown in Figure 5.

[0075] As is clear from Fig. 5, in the compositions of 16 dosages and the control group, Bifidobacterium pseudocatenulatum entered the logarithmic growth phase at almost the same time. As is clear from Fig. 6, in the stationary phase, the compositions of 4:10:1, 4:4:1, 8:8:2, 2:8:2, 9 / 2:2:1 / 2, 8:2:2, 2:11:1 / 2, etc. all promoted the growth of Bifidobacterium pseudocatenulatum and improved the OD 600 value. Particularly in the composition of 4:10:1, the growth of Bifidobacterium pseudocatenulatum was most significantly promoted, being about 1.8 times the OD 600 of the control group. In the compositions of the dosages of 4:10:1, 4:4:1, and 8:8:2, the stationary phase of Bifidobacterium pseudocatenulatum became longer, and in these three dosages of compositions, the nutrients utilized by Bifidobacterium pseudocatenulatum became more sufficient. In the compositions of 2:8:2, 9 / 2:2:1 / 2, 8:2:2, 2:11:1 / 2, etc., there was also a tendency to extend the stationary phase of Bifidobacterium pseudocatenulatum, while the stationary phase of Bifidobacterium pseudocatenulatum under the compositions of other dosages and the control conditions was short and entered the decline phase immediately. Considering comprehensively the growth promotion effect of the composition on bifidobacteria, a preferred embodiment is that the β-glucan in the composition is 2 - 8 times the reference dosage, N-acetylneuraminic acid is 2 - 11 times the reference dosage, lactoferrin is 0.5 - 2 times the reference dosage, and the concentrations are 0.1275 - 0.5100 mg / mL, 0.1029 - 0.5660 mg / mL, 0.0230 - 0.0918 mg / mL respectively.

[0076] Example 6: Growth of Bifidobacterium pseudocatenulatum in MRS medium with appropriate amounts of β-glucan, N-acetylneuraminic acid, lactoferrin and the composition According to Example 2, the appropriate dose of β-glucan to promote the growth of Bifidobacterium pseudocatenulatum was four times the standard dose. According to Example 3, the optimal dose of N-acetylneuraminic acid was four times the standard dose. According to Example 4, the optimal dose of lactoferrin was the standard dose (1x). According to Example 5, the appropriate doses of the composition were combinations of the standard doses of the three components at ratios of 4:10:1, 4:4:1, 8:8:2, 2:8:2, 9 / 2:2:1 / 2, 8:2:2, and 2:11:1 / 2, respectively. Two generations of continuously activated Bifidobacterium pseudocatenulatum were placed in a sterile centrifuge tube (1 mL), centrifuged at 5000 r / min for 15 minutes, discarded the upper layer to obtain the bacterial sludge, which was then resuspended in 1 mL of sterile saline. This sludge was then inoculated into reduced-sugar MRS medium containing 2% (V / V) optimal amounts of the three types of β-glucan, N-acetylneuraminic acid, lactoferrin, and seven types of appropriate compositions. As a blank control, reduced-sugar MRS medium without β-glucan, N-acetylneuraminic acid, lactoferrin, or any of the compositions was also inoculated. The plates were placed in a microplate reader and incubated anaerobically at 37°C for 36 hours, during which the OD of the culture medium was observed. 600 The ΔOD of Bifidobacterium pseudocatenulatum was measured at 4-hour intervals. Appropriate amounts of β-glucan, N-acetylneuraminic acid, lactoferrin, and the composition were used to culture the composition. 600 Figure 7 shows the changes over time (excluding the blank control). Specific values ​​are shown in Tables 1, 2, and 3.

[0077] [Table 1] JPEG0007829719000002.jpg244156JPEG0007829719000003.jpg19152

[0078] [Table 2] JPEG0007829719000005.jpg249157JPEG0007829719000006.jpg78157

[0079] [Table 3] JPEG0007829719000008.jpg246159JPEG0007829719000009.jpg22151

[0080] As can be seen from Figure 7, β-glucan (4 times the standard dose), N-acetylneuraminic acid (4 times the standard dose), and lactoferrin (1 time the standard dose) were all able to promote the proliferation of Bifidobacterium pseudocatenulatum individually (ΔOD 600nm The number was not zero.) The seven proportions of compositions selected in this example (4:10:1, 4:4:1, 8:8:2, 2:8:2, 9 / 2:2:1 / 2, 8:2:2, 2:11:1 / 2) also promoted the growth of Bifidobacterium pseudocatenulatum (ΔOD 600nm It was not zero. ), ΔOD 600nm As the culture time progressed, both groups maintained an increasing trend. This indicates that Bifidobacterium pseudocatenulatum maintained good and smooth growth as the culture time increased, while the control group rapidly entered a decline phase in the later stages. Therefore, the composition and control OD 600nm The difference becomes large, and the ΔOD of the composition 600nm It can be seen that the increase became more pronounced. From the data in Tables 1, 2, and 3, the ΔOD under the culture conditions of seven different proportions of composition can be seen. 600nm In many cases, ΔOD is observed under the same time-dependent culture conditions for β-glucan (4x standard dose), N-acetylneuraminic acid (4x standard dose), and lactoferrin (1x standard dose) alone. 600nm The values ​​were significantly higher than (P<0.05, P<0.01, or P<0.001), and in particular, compositions with the ratios 4:4:1, 8:8:2, 4:10:1, 8:2:2, and 2:11:1 / 2 showed a ΔOD ratio of significantly higher values. 600nmThe values ​​were higher, and this significant difference lasted longer (from 8 hours to 36 hours). Among these compositions, under the 4:10:1 culture conditions, ΔOD was also higher. 600nm The value was highest, and the significant difference lasted the longest from 4 hours to 36 hours of culture, compared to the culture conditions of β-glucan alone (4 times the standard dose), N-acetylneuraminic acid (4 times the standard dose), and lactoferrin (1 time the standard dose). From the above data, it can be seen that the seven compositions selected in this example can all promote the growth of Bifidobacterium pseudocatenulatum to varying degrees, and that β-glucan, N-acetylneuraminic acid, and lactoferrin exert a synergistic effect on the growth of Bifidobacterium pseudocatenulatum. The conditions for bacterial growth and reproduction include sufficient nutrients, appropriate pH value, appropriate temperature, and necessary gas environment. Bacteria have a large surface area, a vigorous metabolism, various types of metabolism, rapid growth and reproduction, and very complex growth patterns. In examples of promoting the growth of probiotics, if the promoting effect of the composition is greater than the promoting effect of any single substance in the composition, the composition has a synergistic effect, i.e., the OD of the composition medium inoculated with the bacterial strain. 600 The value is the OD of any single substance in the culture medium. 600 It is considered to be greater than the value. For example, Chinese patent application No. CN202110770059.9 discloses that a composition combining longan, octopus, and jujube has a higher effect in promoting the growth of complex probiotic strains than polysaccharides alone, and that the composition has a synergistic effect as probiotics.

[0081] Based on the above, the most preferred composition ratio is 2 to 8 times the standard dose of β-glucan, 2 to 11 times the standard dose of N-acetylneuraminic acid, and 0.5 to 2 times the standard dose of lactoferrin. Compositions with concentrations of 0.1275 to 0.5100 mg / mL, 0.1029 to 0.5660 mg / mL, and 0.0230 to 0.0918 mg / mL, respectively, can effectively promote the growth of Bifidobacterium pseudocatenulatum, and it has been further demonstrated that there is a synergistic effect among the three. This composition can promote the growth of Bifidobacterium pseudocatenulatum by approximately 1.8 times compared to the control group (conditions without β-glucan, N-acetylneuraminic acid, and lactoferrin), provide Bifidobacterium pseudocatenulatum with more nutrients, extend the stationary phase of Bifidobacterium pseudocatenulatum, and delay the decline phase. Therefore, it can increase Bifidobacterium pseudocatenulatum, a potential probiotic in the intestinal tract, and improve intestinal health. [Industrial applicability]

[0082] The composition according to the present invention is widely applicable to industries such as food and health foods.

Claims

1. Basic nutritional components, An additive containing 0.1275 to 0.5100 mg / mL of β-glucan, as well as N-acetylneuraminic acid and lactoferrin, A culture medium composition for promoting the growth of intestinal bifidobacteria, comprising The mass ratio of β-glucan, N-acetylneuraminic acid, and lactoferrin is (0.10-0.60):(0.08-0.70):(0.018-0.20) by dry weight. The β-glucan is yeast β-glucan, The composition exists in the form of an aqueous solution or a semi-solid, A culture medium composition for promoting the growth of intestinal bifidobacteria, characterized in that the intestinal bifidobacteria is Bifidobacterium pseudocatenulatum.

2. The composition according to claim 1, characterized in that the N-acetylneuraminic acid is N-acetylneuraminic acid derived from milk, N-acetylneuraminic acid derived from swiftlet nest, or N-acetylneuraminic acid obtained by biofermentation.

3. The composition according to claim 1, characterized in that the basic nutritional components include one or more of the following: protein components, lipid components, sugar components, vitamin components, mineral components, and pH adjusting components.

4. Use of the composition according to any one of claims 1 to 3 in promoting the growth of bifidobacteria, wherein the composition is used to promote the growth of bifidobacteria under in vitro anaerobic conditions.

5. A composition having an effect of promoting the growth of intestinal bifidobacteria, comprising 0.1275 to 0.5100 mg / mL of β-glucan, as well as N-acetylneuraminic acid and lactoferrin, Furthermore, the mass ratio of β-glucan, N-acetylneuraminic acid, and lactoferrin is (0.10-0.60):(0.08-0.70):(0.018-0.20) by dry weight. The β-glucan is yeast β-glucan, The composition having the effect of promoting the growth of intestinal bifidobacteria is a liquid, semi-solid, or solid. A composition having an effect of promoting the growth of intestinal bifidobacteria, characterized in that the intestinal bifidobacteria is Bifidobacterium pseudocatenulatum.

6. It may optionally contain other nutrients. The composition having an effect of promoting the growth of intestinal bifidobacteria according to claim 5, characterized in that the other nutritional components include milk-containing components, meat product components, functional additives and / or any food-permissible additives.

Images